Assignee
MENDUS B V
NL·3 granted patents·6 pending applications·1 citations·filing 2021–2025
Top patents by PatentIndex Score
9 records- 0178US12091681B2Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapyMENDUS B V·Filed 2021·Granted Sep 17, 2024·1 cites·30 claims
- 0267US2025084376A1Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapyMENDUS B V·Filed 2024·Application pending·0 cites
- 0363US12397055B2Methods of tumor vaccinationMENDUS B V·Filed 2022·Granted Aug 26, 2025·0 cites·26 claims
- 0463US2026048126A1Methods of tumor vaccinationMENDUS B V·Filed 2025·Application pending·0 cites
- 0561US2026014255A1Use of leukemia-derived cells in ovarian cancer vaccinesMENDUS B V·Filed 2025·Application pending·0 cites
- 0660US12364758B2Use of leukemia-derived cells in ovarian cancer vaccinesMENDUS B V·Filed 2021·Granted Jul 22, 2025·0 cites·13 claims
- 0758US2024002800A1Use of leukemia-derived cells for enhancing natural killer (nk) cell therapyMENDUS B V·Filed 2023·Application pending·0 cites
- 0857US2023355760A1Modified cells of leukemic origin and a pd-l1 antibody for enhancing the efficacy of cancer cell therapyMENDUS B V·Filed 2023·Application pending·0 cites
- 0955US2024173408A1Prognostic biomarkers for cancer relapse vaccination and the use thereofMENDUS B V·Filed 2023·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →